A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
Recruiting in Palo Alto (17 mi)
+17 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Takeda
No Placebo Group
Trial Summary
What is the purpose of this trial?
The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe \[EU\] and Canada \[CAN\]). Data will be collected retrospectively from medical charts. No study medicines will be provided to participants in this study.
Research Team
SD
Study Director
Principal Investigator
Takeda
Eligibility Criteria
Inclusion Criteria
Received an HSCT after January 1, 2016.
Diagnosed with CMV infection any time after the HSCT date.
resistant to currently available anti-CMV agent; OR refractory to currently available anti-CMV agent; OR intolerant to currently available anti-CMV agent.
See 7 more
Treatment Details
Interventions
- No study medicines will be provided ()
Find a Clinic Near You
Who Is Running the Clinical Trial?
Takeda
Lead Sponsor
Trials
1,255
Recruited
4,219,000+
Dr. Naoyoshi Hirota
Takeda
Chief Medical Officer since 2020
MD from University of Tokyo
Christophe Weber
Takeda
Chief Executive Officer since 2015
PhD in Molecular Biology from Université de Montpellier